Day: August 15, 2024

•   Revenue grew 17% year-over-year, or 23% on a constant currency basis to $664 million•   On-Demand GMV grew 13% year-over-year, or 18% on a constant currency basis to $4.4 billion•   Operating Loss improved by $121 million year-over-year to $(56) million•   Adjusted EBITDA improved by $81 million year-over-year to $64 million SINGAPORE, Aug. 15, 2024 (GLOBE NEWSWIRE) — Grab Holdings Limited (NASDAQ: GRAB) today announced unaudited financial results for the second quarter ended June 30, 2024. “We continued to harness the strength of the Grab ecosystem, and improved the usage frequency and reliability of our products and services. During the quarter, we achieved a new milestone, serving more users than ever at a record high of 41 million MTUs while delivering continued profitable growth at scale,” said Anthony Tan,...

Secured Medicare price assignment for the CompuFlo® Epidural System in multiple U.S. states Gross margin for the second quarter of 2024 increased to 76.1% from 65.0% for the same period last year driven by an increase in U.S. e-commerce sales ROSELAND, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2024. Arjan Haverhals, CEO and President of Milestone Scientific, commented, “We are successfully advancing our reimbursement strategy for the CompuFlo® Epidural System, aimed at achieving nationwide coverage. Last month, we reached a significant milestone as we were granted a Medicare Part B Physician...

Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Aug. 15, 2024 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the second quarter ended June 30, 2024 and provided an update on recent corporate developments. “The first half of 2024 was marked by considerable corporate and clinical progress across the organization. We were encouraged by the bolus of data we presented at ASCO and EHA as they underscore the potential of a prexigebersen combination regimen as a safe and effective treatment for some of the most vulnerable cancer patients,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path...

MISSISSAUGA, Ontario, Aug. 15, 2024 (GLOBE NEWSWIRE) — Next Hydrogen Solutions Inc. (the “Company” or “Next Hydrogen”) (TSXV:NXH, OTC:NXHSF), a designer and manufacturer of electrolyzers, is pleased to report its financial results for the second quarter ended June 30, 2024. “We are pleased to report that our second-generation system is in extended Factory Acceptance Testing which is the final stage prior to demonstration at an external customer site. Further, we are gaining traction with strategic partners and secured an order to deliver a green hydrogen production unit to demonstrate our unique capabilities for low-cost green ammonia production,” said Raveel Afzaal, President & CEO. “We remain grateful to our government for its support on our journey through $2M from Federal Economic Development Agency for Southern Ontario...